Mirabegron (Betmiga®)

Assessment Status Rapid Review Complete
Drug Mirabegron
Brand Betmiga®
Indication Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
Assessment Process
Rapid review commissioned 19/12/2012
Rapid review completed 12/03/2013
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended